Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT02283762 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02283762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
January 15, 2015
Completion date
March 28, 2019
Enrollment
121 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

scleroderma, systemic